Primitive squamous cell carcinoma of the breast (SCCB): case report of an uncommon variant of metaplastic carcinoma

Punzo, Clelia

doi:10.11138/gchir/2017.38.3.139

Cited by 9 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SATO’s ( 24 ) research have shown that patients with BSqCC had a median overall disease-free survival of only 20 months; and the 5-year disease-free survival rate was 26%; the 5-year median survival was 37 months; and the 5-year overall survival rate was only 40%. Another study of 11 patients with primary squamous cell carcinoma of the breast who were treated and followed up for 30 years reported a 5-year survival rate of 67% ( 25 ). Our study showed that the median survival time was 44 months; the 3-year survival rate was 62.9%; the 5-year survival rate was 54.4%; and the 10-year survival rate was 41.4%.…”

Section: Discussionmentioning

confidence: 99%

Prognostic factors for breast cancer squamous cell carcinoma and nomogram development for prediction: population-based research

Cheng¹,

Han²,

Zhang³

et al. 2019

Transl. Cancer Res.

View full text Add to dashboard Cite

Background: To investigate the prognostic survival factors of breast squamous cell carcinoma (BSqCC) and develop a comprehensive nomogram for predicting the survival of breast cancer squamous cell carcinoma. Methods: Data were obtained from the Surveillance, Epidemiology, and End Results (SEER) database to identify patients diagnosed with BSqCC from 1973 to 2015. The data was obtained using SEER Stat 8.3.4 software, collated, and analyzed by Excel 2016 software and SPSS (v25.0). Kaplan-Meier curves were used for survival analysis. The variables obtained by univariate analysis were introduced into the Cox proportional hazard model for multivariate analysis. The risk factors affecting the prognosis of BSqCC were obtained. P<0.05 was considered statistically significant. The independent prognostic factors of BSqCC were integrated and used to construct nomograms.Results: A total of 739 patients with BSqCC was included. The median age of diagnosis was 66 years. In most cases, the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) was negative. One-third of the cases underwent breast-conserving surgery, and more than half of the cases underwent mastectomy (unilateral or bilateral). The 1-year survival rate was 81.2%, the 3-year survival rate was 62.9%, the 5-year survival rate was 54.4%, and the 10-year survival rate was 41.4%. Age (χ 2 =71.050, P<0.001), marital status (χ 2 =37.560, P<0.001), tumor size (χ 2 =27.931, P<0.001), surgical procedure (χ 2 =74.185, P<0.001), the number of positive lymph nodes (χ 2 =38.542, P<0.001), and the primary site (χ 2 =59.217, P<0.001) were significantly correlated with patient survival time. Among them,

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic factors for breast cancer squamous cell carcinoma and nomogram development for prediction: population-based research

Cheng¹,

Han²,

Zhang³

et al. 2019

Transl. Cancer Res.

View full text Add to dashboard Cite

show abstract

“…The pathological diagnostic criteria of MSCCB include: a) more than 90% of the tumor cells are squamous, and other components could include spindle cells, ductal cells, osteocytes, chondrocytes, and striated muscle cells; [6][7][8] b) the origin is independent of primary SCC in a distant site from the skin; and c) is possible after excluding the nipple or the overlying skin primary lesion. 5,8,12,13 When SCC is found in the breast, the origin of the lesion should be sought due to the rarity of MSCCB. Extramammary SCCs have a tendency to metastasize to the breast; the most common primary sites are lung, esophagus, cervix, and urinary bladder.…”

Section: Introductionmentioning

confidence: 99%

<p>SOX10 – A Novel Marker for the Differential Diagnosis of Breast Metaplastic Squamous Cell Carcinoma</p>

Qi¹,

Hu²,

Xiao³

et al. 2020

CMAR

View full text Add to dashboard Cite

Introduction: Differential diagnosis of metaplastic squamous cell carcinoma of breast (MSCCB) is difficult. In particular, in terms of metastatic MSCCB, because of the low speciality of traditional markers such as mammaglobin, gross cystic disease fluid protein-15 (GCDFP-15) and GATA binding protein 3 (GATA3), the most common problem is differentiating the spread of MSCCB to the lung from a primary lung squamous cell carcinoma. It is urgently required to explore a novel marker to aid in differential diagnosis. Aim: The aim of this study is to explore a novel marker to aid in the differential diagnosis of MSCCB from other squamous cell carcinomas (SCC) in other organs. Methods: We tested the expression of SOX10 in 375 human SCC specimens with immunohistochemistry (IHC). Results: In a series of 20 MSCCB, 9 (45%) were positive for SOX10. All of them were triple-negative MSCCB. Conversely, SOX10 was totally negative in another 205 SCC originating from lung, skin, cervix, oral mucosa, and esophagus. In a series of 150 triplenegative breast cancer and their metastatic foci, SOX10 labeling in the primary tumor and metastasis was 78% and 79.3%, respectively, and the agreement rate was 97.3% (P>0.05). Conclusion: Our findings demonstrate that SOX10 was recommended for differentiating MSCCB from non-mammary metastasis to the breast, as well as for distinguishing primary SCC from metastatic MSCCB, and SOX10 may be valuable in the pathological diagnosis of breast-derived metaplastic squamous cell carcinoma.

show abstract

“…Other authors, however, hypothesize that it may originate from myoepithelial cells [ 7 , 8 ]. In our experience, we observed another case of squamous carcinoma in an elderly woman, in whom the clinical onset was associated with an inflammatory cyst [ 9 ].…”

Section: Discussionmentioning

confidence: 99%

Metaplastic squamous cell breast cancer: A case report and treatment strategy during covid-19 pandemic

Tomasicchio¹,

Rizzi²,

Stucci³

et al. 2021

International Journal of Surgery Case Reports

View full text Add to dashboard Cite

Highlights Squamous cell cancer is one of the rarest forms of breast cancer with an incidence of 0.1–0.4% of all breast malignancies. Clinical and imaging ﬁndings in squamous cell cancer can mimic those of a benign disease. Aggressive and rapidly-evolving tumour without specific clinical and radiological features. No well-defined guidelines for the treatment of this rare cancer form. Role of Covid-19 pandemic in the delay of correct oncological treatment.

show abstract

Primitive squamous cell carcinoma of the breast (SCCB): case report of an uncommon variant of metaplastic carcinoma

Abstract: SUMMARY: Primitive squamous cell carcinoma of the breast (SCCB): case report of an uncommon variant of metaplastic carcinoma.

Cited by 9 publications

References 9 publications

Prognostic factors for breast cancer squamous cell carcinoma and nomogram development for prediction: population-based research

Prognostic factors for breast cancer squamous cell carcinoma and nomogram development for prediction: population-based research

<p>SOX10 – A Novel Marker for the Differential Diagnosis of Breast Metaplastic Squamous Cell Carcinoma</p>

Metaplastic squamous cell breast cancer: A case report and treatment strategy during covid-19 pandemic

Contact Info

Product

Resources

About